Improved survival with immunotherapy for microsatellite unstable colorectal cancer with peritoneal metastases.
Rhami KhorfanShaina SedighimDavid Caba-MolinaThuy B TranMaheswari SenthilMichael P O'LearyOliver S EngPublished in: Journal of surgical oncology (2024)
Immunotherapy was associated with significantly better survival compared to chemotherapy in MSI-high CRPM. Two-year OS with systemic + CRS was 68.4%. Despite its role in guiding treatment, MSI testing remains low for these patients.